Search

Your search keyword '"Schuchter L"' showing total 175 results
Start Over Author "Schuchter L"
175 results on '"Schuchter L"'

8. Abstract P6-10-08: Preliminary results of a first in human Phase 1 clinical trial to demonstrate safety and feasibility of chimeric antigen receptor T (CART) cells directed against c-Met in the treatment of breast cancer

Author

Tchou, J, primary, Zhang, PJ, additional, Levine, BL, additional, Zhao, Y, additional, Matro, J, additional, DeMichele, A, additional, Amy, C, additional, Schuchter, L, additional, Plesa, G, additional, Vonderheide, RH, additional, and June, C, additional

Published
2017
Full Text
View/download PDF

9. The state of melanoma: challenges and opportunities

Author

Merlino, G, Herlyn, M, Fisher, DE, Bastian, BC, Flaherty, KT, Davies, MA, Wargo, JA, Curiel-Lewandrowski, C, Weber, MJ, Leachman, SA, Soengas, MS, McMahon, M, Harbour, JW, Swetter, SM, Aplin, AE, Atkins, MB, Bosenberg, MW, Dummer, R, Gershenwald, JE, Halpern, AC, Herlyn, D, Karakousis, GC, Kirkwood, JM, Krauthammer, M, Lo, RS, Long, GV, McArthur, G, Ribas, A, Schuchter, L, Sosman, JA, Smalley, KS, Steeg, P, Thomas, NE, Tsao, H, Tueting, T, Weeraratna, A, Xu, G, Lomax, R, Martin, A, Silverstein, S, Turnham, T, Ronai, ZA, Merlino, G, Herlyn, M, Fisher, DE, Bastian, BC, Flaherty, KT, Davies, MA, Wargo, JA, Curiel-Lewandrowski, C, Weber, MJ, Leachman, SA, Soengas, MS, McMahon, M, Harbour, JW, Swetter, SM, Aplin, AE, Atkins, MB, Bosenberg, MW, Dummer, R, Gershenwald, JE, Halpern, AC, Herlyn, D, Karakousis, GC, Kirkwood, JM, Krauthammer, M, Lo, RS, Long, GV, McArthur, G, Ribas, A, Schuchter, L, Sosman, JA, Smalley, KS, Steeg, P, Thomas, NE, Tsao, H, Tueting, T, Weeraratna, A, Xu, G, Lomax, R, Martin, A, Silverstein, S, Turnham, T, and Ronai, ZA

Abstract

The Melanoma Research Foundation (MRF) has charted a comprehensive assessment of the current state of melanoma research and care. Intensive discussions among members of the MRF Scientific Advisory Council and Breakthrough Consortium, a group that included clinicians and scientists, focused on four thematic areas - diagnosis/early detection, prevention, tumor cell dormancy (including metastasis), and therapy (response and resistance). These discussions extended over the course of 2015 and culminated at the Society of Melanoma Research 2015 International Congress in November. Each of the four groups has outlined their thoughts as per the current status, challenges, and opportunities in the four respective areas. The current state and immediate and long-term needs of the melanoma field, from basic research to clinical management, are presented in the following report.

Published
2016

10. 23 Clinical Status of RAF/MEK Inhibitors

Author

Weber, J., primary, Daud, A., additional, Infante, J., additional, Sosman, J., additional, Flaherty, K., additional, Kefford, R., additional, Hamid, O., additional, Schuchter, L., additional, Patel, K., additional, and Gonzalez, R., additional

Published
2012
Full Text
View/download PDF

11. Phase II Three-Arm Randomised Study of the Braf Inhibitor (BRAFI) Dabrafenib Alone vs Combination with Mek1/2 Inhibitor (MEKI) Trametinib in Pts with Braf V600 Mutation-Positive Metastatic Melanoma (MM)

Author

Long, G.V., primary, Sosman, J.A., additional, Daud, A.I., additional, Weber, J.S., additional, Flaherty, K.T., additional, Infante, J.R., additional, Hamid, O., additional, Schuchter, L., additional, Cebon, J.S., additional, Puzanov, I., additional, Algazi, A.P., additional, Kudchakar, R., additional, Lewis, K., additional, Hwu, W., additional, Kefford, R.F., additional, Sun, P., additional, Little, S.M., additional, Gonzalez, R., additional, Patel, K., additional, and Kim, K.B., additional

Published
2012
Full Text
View/download PDF

12. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.

Author

Ribas, A., primary, Kim, K. B., additional, Schuchter, L. M., additional, Gonzalez, R., additional, Pavlick, A. C., additional, Weber, J. S., additional, McArthur, G. A., additional, Hutson, T. E., additional, Flaherty, K. T., additional, Moschos, S. J., additional, Lawrence, D. P., additional, Hersey, P., additional, Kefford, R. F., additional, Chmielowski, B., additional, Puzanov, I., additional, Li, J., additional, Nolop, K. B., additional, Lee, R. J., additional, Joe, A. K., additional, and Sosman, J. A., additional

Published
2011
Full Text
View/download PDF

13. A phase 0 exploratory study to assess the pharmacodynamic effects of single intratumoral dose of a novel bispecific targeting/immune-activating agent on the melanoma tumor microenvironment.

Author

Fecher, L. A., primary, McGrath, Y., additional, Williams, D. D., additional, Hassan, N. J., additional, Kalos, M., additional, Schuchter, L. M., additional, Amaravadi, R. K., additional, Chew, A., additional, Veloso, E. A., additional, Czerniecki, B. J., additional, Karakousis, G., additional, Linette, G. P., additional, Jakobsen, B. K., additional, and June, C. H., additional

Published
2011
Full Text
View/download PDF

20. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites

Author

Morton, D. L., primary, Mozzillo, N., additional, Thompson, J. F., additional, Kelley, M. C., additional, Faries, M., additional, Wagner, J., additional, Schneebaum, S., additional, Schuchter, L., additional, Gammon, G., additional, and Elashoff, R., additional

Published
2007
Full Text
View/download PDF

21. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

Author

Eisen, T, primary, Ahmad, T, additional, Flaherty, K T, additional, Gore, M, additional, Kaye, S, additional, Marais, R, additional, Gibbens, I, additional, Hackett, S, additional, James, M, additional, Schuchter, L M, additional, Nathanson, K L, additional, Xia, C, additional, Simantov, R, additional, Schwartz, B, additional, Poulin-Costello, M, additional, O'Dwyer, P J, additional, and Ratain, M J, additional

Published
2006
Full Text
View/download PDF

30. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer.

Author

Greco, F A, primary, Figlin, R, additional, York, M, additional, Einhorn, L, additional, Schilsky, R, additional, Marshall, E M, additional, Buys, S S, additional, Froimtchuk, M J, additional, Schuller, J, additional, Schuchter, L, additional, Buyse, M, additional, Ritter, L, additional, Man, A, additional, and Yap, A K, additional

Published
1996
Full Text
View/download PDF

38. Early stage (I, II, III) melanoma.

Author

Sondak, Vernon, Ross, Merrick, Schuchter, Lynn, Sondak, V K, Ross, M I, and Schuchter, L M

Subjects
MELANOMA treatment, BIOPSY, SURGICAL excision, LYMPH nodes, LYMPH node surgery, MELANOMA, SKIN tumors, TUMOR classification, TUMOR treatment
Abstract

Metastatic melanoma beyond the regional nodes (American Joint Committee on Cancer stage IV) is a highly lethal disease. Few affected individuals survive beyond 5 years despite aggressive treatment. Clearly, effective adjuvant therapies to prevent the development of stage IV disease in at-risk patients are worthwhile and acceptable to patients, even if they are associated with significant toxicities. Improvements in our understanding of the prognosis and staging of melanoma have allowed us to better categorize patients based on their risk of developing metastatic disease, permitting the development of logical strategies using adjuvant therapies with toxicity profiles that are appropriate based on the level of risk for recurrence. Adherence to the standards of care for the surgical management of melanoma patients with high-risk primary disease or regional disease will help optimize the benefit that can be derived from adjuvant therapy. Clinical trials remain critically important as we seek to improve the outcome for melanoma patients, but for high-risk melanoma patients outside the context of clinical trials, adjuvant therapy with high-dose interferon-alfa2b should be considered a standard treatment option. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

39. Update in oncology.

Author

Schuchter, Lynn M., Haller, Daniel G., Schuchter, L M, and Haller, D G

Subjects
ONCOLOGY, BREAST cancer, MULTIPLE myeloma, COLON cancer, PROSTATE cancer, BREAST tumor treatment, MULTIPLE myeloma treatment, TUMOR treatment, RECTUM tumors, COLON tumors, PROSTATE tumors treatment, CERVIX uteri tumors
Abstract

Presents updates in oncology. Breast cancer; Cervical cancer; Multiple myeloma; Colorectal cancer; Prostate cancer.

Published
2000
Full Text
View/download PDF

45. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon.

Author

Alpaugh, R, Mehren, Margaret, Palazzo, Irma, Atkins, Michael, Sparano, Joseph, Schuchter, Lynn, Weiner, Louis, Dutcher, Janice, Alpaugh, R K, von Mehren, M, Palazzo, I, Atkins, M B, Sparano, J A, Schuchter, L, Weiner, L M, and Dutcher, J P

Abstract

The inflammatory tumor lymphocytic infiltrates and spontaneous tumor regressions seen in patients with metastatic malignant melanomas suggest a cellular immune involvement. Enhancement of such responses has been the goal of R24 (GD3 ganglioside-specific) monoclonal antibody trials, alone and in combination with other agents. This study reports the results of 21 patients treated in a phase IB trial employing R24 (0, 5, 25, 50 mg/m2) administered by continuous i.v. infusion on days 1-5 followed by 3 MU each of interleukin-2 (IL-2) and alpha interferon (alpha-IFN) given subcutaneously on days 8-12, 15-19 and 22-26. R24-related toxicities occurred pre-dominantly at the 25 and 50 mg/m2 doses. One patient (50 mg/m2 R24) exhibited a dose-limiting Grade 4 anaphylaxis. Cytokine-related toxicities required IL-2/alpha-IFN dose reduction in two patients and early termination of treatment in five additional patients. Nine of 20 baseline biopsies showed chronic inflammation; six with lymphocytic tumor infiltration and three where inflammation was confined to the perivascular/peritumoral spaces. No day 8 or 29 biopsies in the R24-treated groups demonstrated treatment-induced tumor lymphocytic infiltrates. However, one patient randomized to no R24 treatment, showed a significant inflammatory tumor lymphocytic infiltration at days 8 and 29. Eighteen of 21 treated patients were evaluable for response. One (5%) patient receiving IL-2/alpha-IFN alone had stable disease lasting 1.5 years. Five (28%) R24, IL-2/alpha-IFN-treated patients had stable disease ranging from 6 to 32 weeks, with one patient remaining alive 2.5 years post-treatment. Although this combined treatment program was generally well tolerated, no objective responses were seen and significant R24-induced tumor lymphocytic infiltrates were not demonstrated. [ABSTRACT FROM AUTHOR]

Published
1998
Full Text
View/download PDF

46. Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy.

Author

Einzig, Avi, Schuchter, Lynn, Recio, Adri, Coatsworth, Susan, Rodriquez, Roberto, Wiernik, Peter, Einzig, A I, Schuchter, L M, Recio, A, Coatsworth, S, Rodriquez, R, and Wiernik, P H

Subjects
ANTINEOPLASTIC agents, CLINICAL trials, COMPARATIVE studies, HYDROCARBONS, INTRAVENOUS therapy, LONGITUDINAL method, RESEARCH methodology, MEDICAL cooperation, MELANOMA, NEUTROPENIA, PACLITAXEL, RESEARCH, RESEARCH funding, EVALUATION research
Abstract

A phase II study was undertaken to evaluate the clinical efficacy and safety of docetaxel in patients with malignant melanoma. Between April 1992 and February 1996, 37 patients with metastatic malignant melanoma and no prior chemotherapy were treated with docetaxel 100 mg m-2 administered intravenously over 1 hour every 21 days. Patients were premedicated prior to each course with dexamethasone and diphenhydramine. Toxicity and follow-up were provided. Objective responses were seen in two out of 35 patients evaluable for response, one complete response and one partial response. These two responses were of a duration of greater than two years. The most common toxicity was grade 4 neutropenia, which occurred in 92% of patients; 49% required hospitalization for an episode of neutropenic fever. Additional patients had reversible grade 3-4 toxicities including nausea, vomiting, diarrhea, stomatitis, arthralgias, myalgias, peripheral neuropathy and fatigue. Eighteen patients had hypersensitivity reactions, two were grade 3-4. Fluid retention, grade 1-3 was observed in seven patients. Alopecia occurred in most patients. Docetaxel has definite but low-level activity against malignant melanoma. Further investigation of this drug should be considered in multidrug combination programs. [ABSTRACT FROM AUTHOR]

Published
1996
Full Text
View/download PDF

47. Diagnosis and management of high-risk and metastatic melanoma

Author

Hollis, G., Recio, A., and Schuchter, L.

Abstract

Objectives: To identify treatment modalities and corresponding nursing implications for the high-risk and metastatic melanoma patient. Data Sources: Textbooks, research articles, and professional experience. Conclusions: Recent advances in the field of melanoma include identification of prognostic factors, refinement of surgical techniques, and identification of effective adjuvant therapy. Novel therapies are currently under investigation. Implications for Nursing Practice: Nurses play a vital role in the treatment of melanoma patients through education regarding their disease and treatment options, patient identification for clinical trials, and intensive monitoring and management for treatment-related side effects.

Published
2003
Full Text
View/download PDF

48. A prognostic model for predicting 10-year survival in patients with primary melanoma

Author

Schuchter, L., Schultz, D.J., Synnestvedt, M., Trock, B.J., Guerry, D., Elder, D.E., Elenitsas, R., Clark, W.H., and Halpern, A.C.

Subjects
Cancer -- Relapse, Health risk assessment -- Research, Melanoma -- Prognosis -- Research, Health, Research, Prognosis
Abstract

According to the authors' abstract of an article published in Annals of Internal Medicine, 'OBJECTIVE: To develop a prognostic model, based on clinical and pathologic data that are routinely available [...]

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results